Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Ono Pharmaceutical Co's 14-Day RSI or its related term are showing as below:
OPHLF's 14-Day RSI is ranked worse than 68.33% of 1045
companies
in the Drug Manufacturers industry
Industry Median: 47.04
vs OPHLF: 34.15
Ono Pharmaceutical Co (OTCPK:OPHLF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Ono Pharmaceutical Co 14-Day RSI Related Terms
OPHLF vs LLY, JNJ, ABBV: 14-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's 14-Day RSI falls into.
Ono Pharmaceutical Co (OTCPK:OPHLF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co (OPHLF) has a 14-Day RSI of 34.15 as of Jul. 23, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ono Pharmaceutical Co and its competitors. According to the industry distribution chart, Ono Pharmaceutical Co ranks #714 out of 1045 companies in the Drug Manufacturers industry, placing it in the top 68.3%.
Is Ono Pharmaceutical Co's 14-Day RSI too high?
Ono Pharmaceutical Co's current 14-Day RSI is 34.15. The Drug Manufacturers industry median 14-Day RSI is 47.04. Ono Pharmaceutical Co's value of 34.15 is 27.4% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #714 out of 1045 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's 14-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #714 out of 1045 companies for 14-Day RSI. This places Ono Pharmaceutical Co in the lower half of its industry. The industry median 14-Day RSI is 47.04. Ono Pharmaceutical Co's value of 34.15 is 27.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 47.04, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current 14-Day RSI of 34.15 is 27.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 47.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current 14-Day RSI is 34.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (OPHLF) is currently considered Fairly Valued. The stock's GF Value™ is $12.82, compared to a current price of $13.38 — trading 4.4% above its estimated fair value. The current 14-Day RSI is 34.15 and 27.4% below the Drug Manufacturers industry median of 47.04. Ono Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Ono Pharmaceutical Co (OPHLF), the current 14-Day RSI is 34.15 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (OPHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.38 is trading 4.4% above its estimated GF Value™ of $12.82.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for OPHLF:
14-Day RSI: 34.15
GF Value™: $12.82 vs. price of $13.38 (4.4% above fair value)
Industry Position: 27.4% below the Drug Manufacturers median (#714 of 1045)
No single metric tells the full story. See the OPHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
79GF Score
Get the complete analysis for OPHLF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPHLF has been successfully added to your 
